In vivo antinociception of potent mu opioid agonist tetrapeptide analogues and comparison with a compact opioid agonist - neurokinin 1 receptor antagonist chimera
详细信息 查看全文
- 作者：Karel Guillemyn (1)
Patrycja Kleczkowska (2)
Alexandre Novoa (1)
Bart Vandormael (1)
Isabelle Van den Eynde (1)
Piotr Kosson (2)
Muhammad Faheem Asim (3)
Peter W Schiller (4)
Mariana Spetea (3)
Andrzej W Lipkowski (2)
Dirk Tourwé (1)
Steven Ballet (1) - 关键词：Opioid tetrapeptides ; dual opioid agonist ; neurokinin antagonist peptidomimetic ; tolerance studies
- 刊名：Molecular Brain
- 出版年：2012
- 出版时间：December 2012
- 年：2012
- 卷：5
- 期：1
- 全文大小：546KB
- 参考文献：1. Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, Hamon M: International Union of Pharmacology. XIII. Classification of Opioid Receptors. / Pharmacol Rev 1996, 48:567-92.
2. McDonald J, Lambert DG: Opioid receptors. / Contin Educ Anaesth Crit Care Pain 2005, 5:22-5. CrossRef
3. Benyamin R, Trescot AM, Datta S, Buenaventura R, Adlaka R, Sehgal N, Glaser SE, Vallejo R: Opioid complications and side effects. / Pain Physician 2008, 11:S105-S120.
4. Swegle JM, Logemann C: Management of common opioid-induced adverse-effects. / Am Fam Phisician 2006, 74:1347-354.
5. Ananthan S: Opioid ligands with mixed μ/δ opioid receptor interactions: an emerging approach to novel analgesics. / AAPS J 2006, 8:E118-E125. CrossRef
6. Horan P, Tallarida RJ, Haaseth RC, Matsunaga TO, Hruby VJ, Porreca F: Antinociceptive interactions of opioid delta receptor agonists with morphine in mice: supra- and sub-additivity. / Life Sci 1992, 50:1535-541. CrossRef
7. Vaught JL, Takemori AE: Differential effects of leucine and methionine enlephalin on morphine-induced analgesia, acute tolerance and dependence. / J Pharmacol Exp Ther 1979, 208:86-0.
8. Abdelhamid EE, Sultana M, Portoghese PS, Takemori AE: Selective blockage of delta opioid receptors prevents the development of morphine tolerance and dependence in mice. / J Pharmacol Exp Ther 1991, 258:299-03.
9. Dietis N, Guerrini R, Calo G, Salvadori S, Rowbotham DJ, Lambert DG: Simultaneous targeting of multiple opioid receptors: a strategy to improve side- effect profile. / Br J Anaesth 2009, 103:38-9. CrossRef
10. Witt KA, Davis TP: CNS Drug Delivery: Opioid Peptides and the Blood-Brain Barrier. / AAPS Journal 2006, 8:E76-E88. CrossRef
11. Egleton RD, Mitchell SA, Huber JD, Palian MM, Polt R, Davis TP: Improved blood-brain barrier penetration and enhanced analgesia of an opioid peptide by glycosylation. / J Pharmacol Ex Ther 2001, 299:967-72.
12. Blanchfield J, Toth I: Lipid, sugar and liposaccharide based delivery systems 2. / Curr Med Chem 2004, 11:2375-382.
13. Borchardt RT: Optimizing oral absorption of peptides using prodrug strategies. / J Control Release 1999, 62:231-38. CrossRef
14. Gentilucci L: New trends in the development of opioid peptide analogues as advanced remedies for pain relief. / Curr Topics Med Chem 2004, 4:19-8. CrossRef
15. Weber SJ, Greene DL, Hruby VJ, Yamamura HI, Porreca F, Davis TP: Whole body and brain distribution of [3H]cyclic [d-Pen2,d-Pen5] enkephalin after intraperitoneal, intravenous, oral and subcutaneous administration. / J Pharmacol Exp Ther 1992, 263:1308-316.
16. Morphy R, Rankovic Z: Designed multiple ligands: an emerging drug discovery paradigm. / J Med Chem 2005, 48:6523-543. CrossRef
17. Morphy R, Rankovic Z: Design of Multitarget Ligands. In / Lead Generation Approaches in Drug Discovery. Hoboken: John Wiley & Sons, Inc.; 2010:141-64. CrossRef
18. Schiller PW: Bi- or multifunctional opioid peptide drugs. / Life Sci 2010, 86:598-03. CrossRef
19. Das N, Dhanawat M, Dash B, Nagarwal NC, Shrivastava SK: Codrug: an efficient approach for drug optimization. / Eur J Pharmacol Sci 2010, 41:571-88. CrossRef
20. Howard M, Al-Ghananeem A, Crooks PA: A novel chemical delivery system comprising an ocular sustained release formulation of a 3α, 17α, 21-trihydroxy-5β- pregnan-20-one-BIS-5-Flouroucil codrug. / Drug Dev Ind Pharm 2007, 33:677-82. CrossRef
21. Boney IM, Foran SE, Marchand JE, Lipkowski AW, Carr DB: Spinal antinociceptive effects of AA501, a novel chimeric peptide wit opioid receptor agonist and tachykinin receptor antagonist moieties. / Eur J Pharmacol 2004, 488:91-9. CrossRef
22. Nair P, Yamamoto T, Kulkarni V, Moye S, Navratilova E, Davis P, Largent T, Ma S-W, Yamamura HI, Vanderah TW, Lai J, Porreca F, Hruby VJ: Novel bifunctional peptides as opioid agonists and NK-1 antagonists. / Adv Exp Med Biol 2009, 611:537-38. CrossRef
23. Yamamoto T, Nair P, Ma S-W, Davis P, Yamamura HI, Vanderah TW, Porreca F, Lai J, Hruby VJ: The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor antagonists with a cystine moiety. / Bioorg Med Chem 2009, 17:7337-343. CrossRef
24. Yamamoto T, Nair P, Largent-Milnes TM, Jacobsen NE, Davis P, Ma S-W, Yamamura HI, Vanderah TW, Porreca F, Lai J, Hruby VJ: Discovery of a potent and efficacious peptide derivative for δ/μ opioid agonist/neurokinin 1 antagonist activity with a 2',6'-dimethyl-L-tyrosine: In vitro, in vivo , and NMR-based structural studies. / J Med Chem 2011, 54:2029-038. CrossRef
25. Rupniak NMJ, Kramer R: Substance P and related tachikinins. In / Neuropharmacology The fifth generation of progress. Edited by: Davis KL, Charney D, Coyle JT et al. Philadelphia: Lippincott Williams & Wilkins; 2002:169-78.
26. King T, Gardell LR, Wang R, Vardanyan A, Ossipov MH, Malan TP Jr, Vanderah TW, Hunt SP, Hruby VJ, Lai J, Porreca F: Role of NK-1 neurotransmission in opioid-induced hyperalgesia. / Pain 2005, 116:276-88. CrossRef
27. King T, Ossipov MH, Vanderah TW, Porreca F, Lai J: Is paradoxical pain induced by sustained opioid exposure and underlying mechanism of opioid antinociceptive tolerance? / Neurosignals 2005, 14:194-05. CrossRef
28. Melchiorri P, Negri L: The Dermorphin Peptide Family. / Gen Pharmac 1996, 27:1099-107. CrossRef
29. Negri L, Lattanzi R, Melchiorri P: Production of antinociception by peripheral administration of [Lys7]Dermorphin, a naturally occurring peptide with high affinity for m-opioid receptors. / Br J Pharmacol 1995, 114:57-6.
30. Usenko AB, Emel'yanowa TG, Myasoedov NF: Dermorphins are naturally opioids with an unique primary structure that determines their biological specificity. / Biol Bull 2002, 29:154-64. CrossRef
31. Vandormael B, Fourla D-D, Gramowski-Vo? A, Kosson P, Weiss DG, Schr?der OH-U, Lipkowski AW, Georgoussi Z, Tourwé D: Superpotent [Dmt 1 ]Dermorphin tetrapeptides containing the 4-aminotetrahydro-2-benzazepin-3-one scaffold with mixed μ/δ opioid receptor agonistic properties. / J Med Chem 2011, 54:7848-859. CrossRef
32. Ballet S, Feytens D, Buysse K, Chung NN, Lemieux C, Tumati S, Keresztes A, Van Duppen J, Lai J, Varga E, Porreca F, Schiller PW, Vanden Broeck J, Tourwé D: Design of novel neurokinin 1 receptor antagonists based on conformationally constrained aromatic amino acids and discovery of a potent chimeric opioid agonist-neurokinin 1 receptor antagonist. / J Med Chem 2011, 54:2467-476. CrossRef
33. Hansen DW Jr, Stapelfeld A, Savage MA, Reichman M, Hammond DL, Haaseth RC, Mosberg HI: Systemic analgesic activity and delta-opioid selectivity in [2,6-dimethyl-Tyr 1 , D-Pen 2 , D-Pen 5 ]enkephalin. / J Med Chem 1992, 35:684-87. CrossRef
34. Ballet S, Frycia A, Piron J, Chung NN, Schiller PW, Kosson P, Lipkowski AW, Tourwé D: Synthesis and biological evaluation of constrained analogues of the opioid peptide H-Tyr-D-Ala-Phe-Gly-NH2 using 4-amino-2-benzazepin-3-one scaffold. / J Peptide Res 2005, 66:222-30. CrossRef
35. Tourwé D, Verschueren K, Frycia A, Davis P, Porreca F, Hruby VJ, Toth G, Jaspers H, Verheyden P, Van Binst G: Conformational restriction of Tyr and Phe side-chain in opioid peptides: Information about preferred and bioactive side-chain topology. / Biopolymers 1996, 38:1-2. CrossRef
36. Tourwé D, Verschueren K, Van Binst G, Davis P, Porreca F, Hruby VJ: Dermorphin sequence with high delta-affinity by fixing the Phe side-chain to trans at alpha-1. / Bioorg Med Chem Lett 1992, 2:1305-308. CrossRef
37. Kleczkowska P, Kosson P, Ballet S, Van den Eynde I, Tsuda Y, Tourwé D, Lipkowski AW: PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects. / Mol Pain 2010, 6:86-2. CrossRef
38. Larson MG: Statistical primer for cardiovascular research. Analysis of variance. / Circulation 2008, 117:115-21. CrossRef
39. Salkind NJ (Ed): Significantly different: using inferential statistics In / Statistics for people who (think they) hate statistics. SAGE Publications, Inc.; 2010:221-38.
40. Misterek K, Maszczynska I, Dorociak A, Gumulka SW, Carr DB, Szyfelbein SK, Lipkowski AW: Spinal co-administration of peptide substance P antagonist increases antinociceptive effect of the opioid peptide biphalin. / Life Sci 1994, 54:939-44. CrossRef
41. Yamamoto T, Nair P, Jacobsen NE, Kulkarni V, Davis P, Ma S-W, Navratilova E, Yamamura HI, Vanderah TW, Porreca F, Lai J, Hruby VJ: Biological and conformational evaluation of bifunctional compounds for opioid receptor agonists and neurokinin 1 receptor antagonists possessing two penicillamines. / J Med Chem 2010, 53:5491-501. CrossRef
42. Schiller PW, Nguyen TMD, Berezowska I, Dupuis S, Weltrowska G, Chung NN, Lemieux C: Synthesis and in vitro opioid activity profiles of DALDA analogues. / Eur J Med Chem 2000, 35:895-01. CrossRef
43. Largent-Milnes TM, Yamamoto T, Nair P, Moulton JW, Hruby VJ, Lai J, Porreca F, Vanderah TW: Spinal or systemic TY005, a peptidic opioid agonist/neurokinin 1 antagonist, attenuates pain with reduced tolerance. / Br J Pharmacol 2010, 161:986-001. CrossRef
44. Maszczynska I, Lipkowski AW, Carr DB, Kream RM: Alternative forms of interaction of substance P and opioids in nociceptive transmission. / Lett Pept Sci 1998, 5:395-98.
45. Hahn EF: Testing and evaluation of opiate analgesics and antagonists. / Methods Find Exp Clin Pharmacol 1985, 7:373-81.
46. D'Amour FE, Smith DL: A method for determining loss of pain sensation. / J Pharmacol Exp Ther 1941, 72:74-9.
47. Schild HO: pA2, a new scale for the measurement of drug antagonism. / Br J Pharmacol 1947, 2:189-06.
48. Merkouris M, Mullaney I, Georgoussi Z, Milligan G: Regulation of spontaneous activity of delta-opioid receptor: studies of inverse agonism in intact cells. / J Neurochem 1997, 69:2115-122. CrossRef
49. DiMaio J, Nguyen TMD, Lemieux C, Schiller PW: Synthesis amd pharmacological characterization in vitro of cyclic enkephalin analogues: effect of the conformational constraints on opioid receptor selectivity. / J Med Chem 1982, 25:1432-438. CrossRef - 作者单位：Karel Guillemyn (1)
Patrycja Kleczkowska (2)
Alexandre Novoa (1)
Bart Vandormael (1)
Isabelle Van den Eynde (1)
Piotr Kosson (2)
Muhammad Faheem Asim (3)
Peter W Schiller (4)
Mariana Spetea (3)
Andrzej W Lipkowski (2)
Dirk Tourwé (1)
Steven Ballet (1)
1. Department of Organic Chemistry, Vrije Universiteit Brussel, Pleinlaan 2, B-1050, Brussels, Belgium
2. Mossakowski Medical Research Centre, Polish Academy of Sciences, Pawinskiego street 5, 02106, Warsaw, Poland
3. Department of Pharmaceutical Chemistry, Institute of Pharmacy and Center for Molecular Biosciences Innsbruck, University of Innsbruck, Innrain 52a, A-6020, Innsbruck, Austria
4. Department of Chemical Biology and Peptide Research, Clinical Research Institute of Montreal, 110 Avenue des Pins Ouest, Montreal, Canada - ISSN：1756-6606
文摘
Background An important limiting factor in the development of centrally acting pharmaceuticals is the blood-brain barrier (BBB). Transport of therapeutic peptides through this highly protective physiological barrier remains a challenge for peptide drug delivery into the central nervous system (CNS). Because the most common strategy to treat moderate to severe pain consists of the activation of opioid receptors in the brain, the development of active opioid peptide analogues as potential analgesics requires compounds with a high resistance to enzymatic degradation and an ability to cross the BBB. Results Herein we report that tetrapeptide analogues of the type H-Dmt1-Xxx2-Yyy3-Gly4-NH2 are transported into the brain after intravenous and subcutaneous administration and are able to activate the μ- and δ opioid receptors more efficiently and over longer periods of time than morphine. Using the hot water tail flick test as the animal model for antinociception, a comparison in potency is presented between a side chain conformationally constrained analogue containing the benzazepine ring (BVD03, Yyy3: Aba), and a "ring opened" analogue (BVD02, Yyy3: Phe). The results show that in addition to the increased lipophilicity through amide bond N-methylation, the conformational constraint introduced at the level of the Phe3 side chain causes a prolonged antinociception. Further replacement of NMe-D-Ala2 by D-Arg2 in the tetrapeptide sequence led to an improved potency as demonstrated by a higher and maintained antinociception for AN81 (Xxx2: D-Arg) vs. BVD03 (Xxx2: NMe-D-Ala). A daily injection of the studied opioid ligands over a time period of 5 days did however result in a substantial decrease in antinociception on the fifth day of the experiment. The compact opioid agonist - NK1 antagonist hybrid SBCHM01 could not circumvent opioid induced tolerance. Conclusions We demonstrated that the introduction of a conformational constraint has an important impact on opioid receptor activation and subsequent antinociception in vivo. Further amino acid substitution allowed to identify AN81 as an opioid ligand able to access the CNS and induce antinociception at very low doses (0.1 mg/kg) over a time period up to 7 hours. However, tolerance became apparent after repetitive i.v. administration of the investigated tetrapeptides. This side effect was also observed with the dual opioid agonist-NK1 receptor antagonist SBCHM01.